Halozyme Therapeutics announced that its CEO Dr. Helen Torley and CFO Darren Snellgrove will participate in investor meetings and fireside chats at three upcoming healthcare conferences in September 2026: Wells Fargo (Sept 9), Morgan Stanley (Sept 15), and H.C. Wainwright (Sept 16). These events provide opportunities for Halozyme to showcase its innovative drug delivery technologies, including ENHANZE®, Hypercon™, and Surf Bio's hyperconcentration technology, which improve patient treatment experiences. Live audio webcasts of the presentations will be available on Halozyme's website, with replays accessible for 90 days. This engagement highlights Halozyme's ongoing efforts to expand its partnerships and commercial presence in the biopharmaceutical industry.
Nvidia has returned a record $26 billion to its shareholders after increasing its dividend by an extraordinary 2,400%. This massive payout highlights the company's strong financial position and commitment to rewarding investors. The significant divid...
Hybrid Power Solutions Inc. has filed a patent application for an advanced AI-powered energy management system designed to optimize hybrid power setups combining battery storage, renewables, generators, and grid connections. The system features machi...
Gold prices stabilized after a week of selling pressure as US private sector job growth slowed significantly in August. The ADP report showed only 38,000 jobs created, below the expected 47,000 and the slowest pace since January. Job losses were nota...
Reaves Utility Income Fund (UTG) offers a compelling 6.68% yield following a 14% selloff, supported by a recent 5% increase in its monthly distribution and a 22-year history of uninterrupted payouts. Despite market fears over rate hikes causing a pri...
Tesla reported record Q2 2026 deliveries of 480,126 vehicles but faced a sharp decline in operating margins due to rising expenses and heavy investment in AI and autonomy technology. Meanwhile, BYD continues to grow steadily with strong sales of plug...
